Villegas A, Ropero P, González F A, Anguita E, Espinós D
Servicio de Hematología y Hemoterapia, Hospital Clínico San Carlos, Madrid, Spain.
Hemoglobin. 2001 Aug;25(3):273-83. doi: 10.1081/hem-100105220.
This work compiles the results of our research on alpha- and beta-thalassemias, and includes a literature review of the molecular genetics of alpha- and beta-thalassemias in Spain. We studied 1,564 subjects with thalassemia (294 with beta-thalassemia and 1,264 with alpha-thalassemia) by molecular biology techniques. In relation to beta-thalassemia, a total of 15 different mutations were characterized in a study of 308 chromosomes belonging to 294 unrelated subjects. Eleven were homozygotes (22 alleles), three compound heterozygotes (6 alleles), and the remaining 280 were heterozygotes (280 alleles). A total of 86.6% of the alleles identified can be grouped into five different mutations [IVS-I-1 (G-->A), IVS-I-6 (T-->C), IVS-I-110 (G-->A), codon 39 (C-->T), codons 8/9 (+G)]. In 14 subjects (4.5%), all heterozygotes, it was not possible to identify the alteration responsible for the beta-thalassemia. For alpha-thalassemia, 911 subjects showed heterozygous alpha(+)-thalassemia (872 with -3.7 kb; 14 with -4.2 kb; two with the deletion of 3.5 kb of DNA, and 23 with nondeletional alpha-thalassemia). Two hundred and thirty-three subjects had homozygous alpha(+)-thalassemia (223 for -alpha(-3.7)/-alpha(-3.7)); one for -alpha(-4.2)/-alpha(-4.2); six for -alpha(-3.7)/-alpha(-4.2); one for -alpha(-3.5)/-alpha(-3.7); one for alphaalpha(Nco)/alphaalpha(Nco); one for alpha(HPh)/alpha(Hph)). One hundred patients presented with heterozygous alpha(0)-thalassemia (18 of whom were progenitors of patients with Hb H disease). The alpha(0) determinant was found in 20 patients with Hb H disease associated with -alpha(-3.7). From the DNA analysis were identified the - -(MED), - -(SEA), - -(SPAN) deletions and the - -(MA) mutations; in three cases, a break that affects the distal portion of the short arm of chromosome 16; one of these was associated with the ATR-16 (alpha-thal with mental retardation) syndrome. Triplication of the alpha genes (alphaalphaalpha(-3.7)/alphaalpha) was found in 25 subjects, 16 of whom were associated with a heterozygous beta-thalassemia. Only one patient was homozygous for the triplication of alpha genes (alphaalphaalpha(-3.7)/alphaalphaalpha(-3.7)) that was associated with a heterozygous beta-thalassemia. In the Mediterranean region preventive programs for thalassemia, based on the detection of heterozygote carriers and genetic advice, are not sufficient to reduce the incidence of newborns with major thalassemia. Prenatal diagnosis of thalassemias has given a new dimension to the prevention of these, but in order to implement this, a knowledge of the mutations and the incidence of these, is essential. This study, therefore, aims to give a general picture of the molecular genetics of thalassemia and its geographical distribution in our area.
这项工作汇编了我们对α地中海贫血和β地中海贫血的研究结果,并包括对西班牙α地中海贫血和β地中海贫血分子遗传学的文献综述。我们通过分子生物学技术研究了1564例地中海贫血患者(294例β地中海贫血患者和1264例α地中海贫血患者)。关于β地中海贫血,在对294名无关受试者的308条染色体进行的研究中,共鉴定出15种不同的突变。其中11例为纯合子(22个等位基因),3例为复合杂合子(6个等位基因),其余280例为杂合子(280个等位基因)。总共86.6%的已鉴定等位基因可归为五种不同的突变[IVS-I-1(G→A)、IVS-I-6(T→C)、IVS-I-110(G→A)、密码子39(C→T)、密码子8/9(+G)]。在14名受试者(4.5%)中,均为杂合子,无法鉴定出导致β地中海贫血的变异。对于α地中海贫血,911名受试者表现为杂合子α(+)地中海贫血(872例为-3.7 kb缺失;14例为-4.2 kb缺失;2例为3.5 kb DNA缺失,23例为非缺失型α地中海贫血)。233名受试者为纯合子α(+)地中海贫血(223例为-α(-3.7)/-α(-3.7);1例为-α(-4.2)/-α(-4.2);6例为-α(-3.7)/-α(-4.2);1例为-α(-3.5)/-α(-3.7);1例为αα(Nco)/αα(Nco);1例为α(HPh)/α(Hph))。100名患者表现为杂合子α(0)地中海贫血(其中18例为Hb H病患者的父母)。在20例与-α(-3.7)相关的Hb H病患者中发现了α(0)决定簇。通过DNA分析鉴定出了--(MED)、--(SEA)、--(SPAN)缺失和--(MA)突变;在3例中,发现一条影响16号染色体短臂远端部分的断裂;其中1例与ATR-16(伴有智力发育迟缓的α地中海贫血)综合征相关。在25名受试者中发现了α基因的三倍体(ααα(-3.7)/αα),其中16例与杂合子β地中海贫血相关。只有1例患者为α基因三倍体的纯合子(ααα(-3.7)/ααα(-3.7)),与杂合子β地中海贫血相关。在地中海地区,基于杂合子携带者检测和遗传咨询的地中海贫血预防计划不足以降低重型地中海贫血新生儿的发病率。地中海贫血的产前诊断为预防这些疾病带来了新的层面,但为了实施这一措施,了解这些突变及其发生率至关重要。因此,本研究旨在全面介绍我们地区地中海贫血的分子遗传学及其地理分布情况。